ArticleScientific reports2018
A systematic evaluation of the biocompatibility of cucurbit[7]uril in mice.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Cucurbiturils in Oxygen Delivery and Their Potential in Anemia Management.Journal of clinical medicine · 2025Review
- Supramolecular Complexation of Quenched Rosamines with Cucurbit[7]Uril: Fluorescence Turn-ON Effect for Super-Resolution Imaging.Journal of the American Chemical Society · 2025Article
- Elucidating the potential of EGFR mutated NSCLC and identifying its multitargeted inhibitors.Scientific reports · 2025Article
- Macrocycle-Based Supramolecular Drug Delivery Systems: A Concise Review.Molecules (Basel, Switzerland) · 2024Review
- Host-Guest Interactions of Ruthenium(II) Arene Complexes with Cucurbit[7/8]uril.Inorganic chemistry · 2024Article
- Supramolecular complexation of phenylephrine by cucurbit[7]uril in aqueous solution.RSC advances · 2024Article
- Overcoming barriers with non-covalent interactions: supramolecular recognition of adamantyl cucurbit[RSC medicinal chemistry · 2024Review
- Evaluation of the Immunosafety of Cucurbit[n]uril In Vivo.Pharmaceutics · 2024Article
- Strategies for enhanced bioavailability of oxime reactivators in the central nervous system.Archives of toxicology · 2023Review
- Controllable DNA hybridization by host-guest complexation-mediated ligand invasion.Nature communications · 2022Article
- The Role of Packing, Dispersion, Electrostatics, and Solvation in High-Affinity Complexes of Cucurbit[n]urils with Uncharged Polar Guests.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Anthracene-Walled Acyclic CB[n] Receptors: in vitro and in vivo Binding Properties toward Drugs of Abuse.ChemMedChem · 2022Article
- In Vitro and In Vivo Sequestration of Methamphetamine by a Sulfated Acyclic CB[n]-Type Receptor.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Reviving chloroquine for anti-SARS-CoV-2 treatment with cucurbit[7]uril-based supramolecular formulation.Chinese chemical letters = Zhongguo hua xue kuai bao · 2021Article
- Cucurbit[7]uril as a Broad-Spectrum Antiviral Agent against Diverse RNA Viruses.Virologica Sinica · 2021Article
- In Vitro and In Vivo Sequestration of Phencyclidine by MeChemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Self Assembled Cages with Mechanically Interlocked Cucurbiturils.Supramolecular chemistry · 2021Article
- Recent advances in supramolecular antidotes.Theranostics · 2021Review
- Cucurbituril Ameliorates Liver Damage Induced by Microcystis aeruginosa in a Mouse Model.Frontiers in chemistry · 2021Article
- Supramolecular hosts as in vivo sequestration agents for pharmaceuticals and toxins.Chemical Society reviews · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As one of the most water-soluble members in the macrocyclic cucurbit[n]uril (CB[n]) family, CB[7] has attracted increasing attention in pharmaceutical and biomedical fields. Despite extensive studies regarding the potential use of CB[7] for biomedical applications, its full safety and toxicity profile in a clinically relevant model is still lacking. Herein we report the full biocompatibility profile of CB[7], administered orally, peritoneally or intravenously in mice, respectively. Body-weight changes showed no significant differences among various groups of mice after they were administered with CB[7] at a single dose of 5 g/kg orally, 500 mg/kg peritoneally and 150 mg/kg intravenously, respectively. Hematology tests, as well as hepatic and renal function biochemical markers tests, of the blood collected from these mice sacrificed 21 days after CB[7] administration all exhibited normal ranges of values that were comparable with those of the control group. Moreover, histopathological analysis on the sections of major organs (including the heart, liver, spleen, lungs and kidneys) and gastrointestinal tissues revealed no detectable injuries and inflammatory cells infiltration. Taken together, these results suggest an excellent biocompatibility profile of CB[7] in mice, which provide important foundations for further investigations and even clinical applications of CB[7] in biomedical areas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.